[b]NBS >>> Investment Highlights[/b]
Divested ownership interest in Suzhou Erye Pharmaceutical Co, increasing its cash position by $12,280,000 - Already received $1,228,000 (10%)
Acute Myocardial Infarction (AMI) therapeutic product development team enrolled the first patient in the PreSERVE Phase 2 clinical trial
Our Progenitor Cell Therapy (PCT) CDMO service business continues to grow and has added new clients in later stage clinical trials setting the stage for expansion into larger and substantially more lucrative commercial manufacturing contracts
Jonathan Sackner-Bernstein, MD, FACC joined the Company. He was Associate Center Director for Technology and Innovation at the U.S. Food and Drug Administration's Center for Devices and Radiological Health
Actively pursuing additional strategic relationships with major pharmaceutical and biotechnology companies in 2012
WBB Securities LLC - UPGRADED TO STRONG BUY - $2.00 12 MONTH TARGET
Symbol is NBS
News Link: http://finance.yahoo.com/q?s=nbs&ql=1
NeoStem Fact Sheet Quick Recap - see below or Full FactSheet PDF link here
June 22, 2012
Fast Facts
Name: NeoStem, Inc.
Industry: Biotech / Cell Therapy
Ticker (Exchange): NBS (NYSE MKT)
All figures as of 6/18/12 except where noted
Stock Price: $0.47
52 Week Range: $0.30 – 1.76
Market Cap: $62.99 million
Average Volume (3 mos): 1,079,033
Shares Outstanding: 129.9 million*
*As of March 31, 2012
NeoStem Subsidiaries
Established Leader in Cell Therapy Services
150 years of combined management expertise in manufacturing, regulatory and commercialization for therapeutics development
$8-10 million in annual historic revenues
Manufactured 30,000+ cell therapy product procedures and delivered 6,000+ cell therapies to patients worldwide for more than 100 clients
50,000 square feet of cGMP manufacturing capability located in North America (East Coast and West Coast)
Large scale manufacturing for clients allows lower costs for internal cell therapy development
• Establish early partnering relationships with goals of commercial manufacturing, equity participation and back-end royalties
Emerging Leader in Cardiovascular Cell Therapy
Lead product, AMR-001, an autologous adult stem cell therapy for the prevention of major adverse cardiac events following acute myocardial infarction (AMI)
Launched Phase 2 clinical trial in 1Q-2012, data readouts expected 2H-2013
Potential for multiple indications beyond STEMI (i.e., congestive heart failure, other related vascular insufficiencies)
PreSERVE AMI Trial Phase 2 Clinical Plan
Indication Post-AMI preservation of cardiac function
Number of Subjects, Sites 160 patients, 34+ sites
Primary Endpoint Increased cardiac perfusion
Amorcyte: Using The CD34+ Natural Repair Mechanism
The body attempts to rescue damaged tissue to prevent ventricular remodeling:
A distress signal (HIF) is induced by hypoxia in the peri- infarct zone
HIF induces syntheses of SDF and VEGF, which mobilize CD34+CXCR4+ cells
The mobilized cells are trophic to the peri-infract zone, preventing apoptosis and effecting neoangiogenesis
AMR-001 is a homogeneous and highly purified cell population enriched for CD34+CXCR4+ cells
In Partnership with Becton Dickinson (20% Owner)
Immunotherapy Platform
• Immune mediated diseases are a result of imbalance between T effector cells and T regulatory cells
• T-reg therapy represents a novel approach for restoring immune balance by enhancing T-reg cell number/function
Opportunities in Regenerative Medicine
Cellular Differentiation with an Eye Toward Macular Degeneration
• Very small embryonic-like stem cells, shown to have several characteristics generally found in embryonic stem cells
• Activities have received awards of > $2.5 million to support this work
Upcoming Milestones
• Advance VSELs into a Phase Ia safety trial for macular degeneration (2013)
• PCT – Secure additional client contracts, establish client partnerships for commercial manufacturing and/or royalties, and expand manufacturing outside the U.S. (2012)
• Closing of divestiture of Suzhou Erye (51% NeoStem owned generic pharmaceutical company) (2012)
• Start Phase I trial in CHF with AMR-001 (2012/2013)
• Complete enrollment of Phase II trial (1H-2013)
• Data readouts for Phase II AMR-001 Trial (2H-2013)
• Athelos - data readout from work under independent physician INDs (1H-2013)
• Secure additional SBIR and/or DoD government grants for VSEL Technology (2012)
Contacts
Collaborations
Dr. Robin L. Smith
Chairman and Chief Executive Officer
212.584.4174
rsmith@neostem.com
Gitanjali Jain Ogawa
Trout Group - Vice President
646.378.2949
gogawa@troutgroup.com
This material contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date hereof, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy, including with respect to the development of AMR-001 and other cell therapeutics, the future of the cell therapeutics industry, and the Company’s divestiture of its interest in Suzhou Erye Pharmaceutical Co., Ltd. The Company’s actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors including those described under the heading "Risk Factors" in the Company’s filings with the Securities and Exchange Commission (www.sec.gov). The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
NeoStem, Inc. (NYSE MKT: NBS)
420 Lexington Avenue, Suite 450
New York, NY 10170
212.584.4180
www.neostem.com
NeoStem, Inc.
420 Lexington Avenue
Suite 450
New York, New York 10170
Telephone: 212-584-4180
Fax: 646-514-7787
Website: www.neostem.com
Conceptus, RTI International Metals Among Stocks Gapping Up Wednesdayat Fox Business(Wed, Aug 1)
Costly Mistakes Crush Dendreon But Upside May Lurkat Seeking Alpha(Wed, Aug 1)
Celsion and Neostem Showing Positive Growth as Biotech Industry Soaring in 2012Marketwire(Tue, Jul 31)
Are Stem Cells Becoming The Next Bull Market In The Biotech Space?at Seeking Alpha(Mon, Jul 30)
NeoStem's Promising VSEL Developments Are Good Signs For The Future Of Cell Therapyat Seeking Alpha(Thu, Jul 26)
Heavy Volume May Mean Heavier Profits In Small Biopharmaceutical Stocksat Seeking Alpha(Mon, Jul 23)
A Big Win For Neostemat Seeking Alpha(Thu, Jul 19)
NeoStem Continues To Rally Behind Its Key Developmentsat Seeking Alpha(Tue, Jul 17)
NeoStem's Subsidiary, Progenitor Cell Therapy, and SOTIO Enter Into a Phase 3 Manufacturing Services AgreementGlobeNewswire(Mon, Jul 16)
» More Headlines for NBS
Information compiled from public sources
NBS Investment Highlights Divested ownership interest in
Top 10 Most Recent News Articles
Texas Plumbing Award Signals Local Service Discipline
A clogged main line is not glamorous, but it is where a local service reputation gets tested for real. Neighborhood Plumbing and Drain has been named a 2026 Best of Texas Award winner in the Plumbing Contractors category, a recognition that matters less as a trophy than as a public signal: customers around Central Texas have noticed the outfit. For anyone watching the...
Continue Reading
Robert Half's Parent Support Earns Fortune Recognition
A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...
Continue Reading
Cedars-Sinai and nference Build a Living Data Engine
Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...
Continue Reading
Point72 Breach Puts Cyber Controls Under the Microscope
Two compromised user accounts can turn a supposedly contained cyber problem into a boardroom headache in a hurry. Point72 Asset Management, the global alternative-investment firm founded by Steven A. Cohen in 2014, has reported a social-engineering incident involving accounts that were used to copy files from limited portions of its IT systems. This is not a trading-loss...
Continue Reading
Rox Taps Dynamics 365 Without Forcing a CRM Reset Yet
Enterprise software buyers hate renovations when a useful extension will do. Rox’s new integration with Microsoft Dynamics 365 Sales, announced November 19, 2026, is built around that unglamorous but very real fact. The company is not asking a Global 2000 sales organization to rip out its customer system, retrain everybody, and pray an AI layer somehow pays for the...
Continue Reading
Carnival Maps a Longer, Broader Bet on Cruise Demand
A cruise operator does not order ships for 2035 because it is feeling timid. Carnival is laying out a long runway of hardware, private-destination capacity and onboard-to-onshore spending hooks, all aimed at keeping guests inside its ecosystem longer. For NYSE:CCL, this is not a next-quarter story. It is a very public statement that management sees enduring appetite for...
Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention
A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...
Continue Reading
Candel’s BLA Delay Puts Disclosure Timing Under Fire
A December filing turned into a mid-2027 wait, and Candel shareholders absorbed the damage in one ugly trading session. On November 13, shares of Candel Therapeutics fell 26% after the company disclosed that its biologics license application, or BLA, for aglatimagene in prostate cancer was no longer expected in December 2026. The revised plan is to submit in the middle of...
Continue Reading
EmTech AI 2027 Puts AI Ambitions Through Reality Test
A three-day gathering cannot settle AI's biggest arguments, but MIT Technology Review has picked the right fight for EmTech AI 2027: make the industry face a Reality Test. The conference runs May 11–13, 2027, at MIT's campus and online, and that theme lands because the AI conversation has spent plenty of time admiring the engine while skipping the ugly maintenance bill....
Continue Reading
Winter Leaks Can Lock In Tarrant Sewer Costs for 2027
Silent toilet seepage has a nasty habit of turning winter into a twelve-month utility hangover. Tarrant County homeowners are heading into the period when some local cities use household water consumption to calculate residential sewer charges for the following year. That is not the sort of detail anybody enjoys thinking about during the holidays, but ignoring it can be...
Continue ReadingTop 5 Most Recently Viewed Articles
Insights from BioRestorative's CEO on Regenerative Medicine
CEO Lance Alstodt Discusses BioRestorative's Vision In a recent interview on “The Big Biz Show,” the dynamic CEO of BioRestorative Therapies, Inc., Lance Alstodt, shared invaluable insights into the company's journey. As a pioneer in regenerative medicine, BioRestorative focuses on innovative stem cell-based therapies aimed at addressing various medical challenges....
Continue Reading
Hargreave Hale AIM VCT PLC NAV Announcement
Hargreave Hale AIM VCT PLC (the “Company”) Net Asset Value Announcement As of the close of business on 16 August 2024, the unaudited Net Asset Value (NAV) for Hargreave Hale AIM VCT plc stands at: NAV per Ordinary share of 1p – 42.03 pence. Contact Information If you need more information, please reach out to: JTC (UK) Limited Uloma Adighibe Alexandria Tivey Email...
Continue Reading
Discover Luxury Living at Toll Brothers' New Community in Texas
Introducing Toll Brothers at George's Ranch In a splendid showcase of luxury living, Toll Brothers, Inc. (NYSE:TOL) has unveiled its newest community, Toll Brothers at George's Ranch, located in the serene surroundings of Boerne, Texas. This exciting development marks an important addition to the San Antonio area, where elegance meets modern design. Grand Opening...
Continue Reading
xLean's TR1 Robot Revolutionizes Cleaning Technology
xLean's Innovative TR1 Takes Center Stage xLean Robotics concluded an exciting showcase at IFA 2025, where its groundbreaking TR1, the world's first dual-form transformable floor washing robot, earned several prestigious awards. This innovative device was recognized as the 'Best in IFA Next Winner' and 'Best in Design Honoree,' and it was featured as one of the 'Top 5...
Continue Reading
Alpha Modus Sues H&M for Patent Infringement Regarding AI Tech
Alpha Modus Files Patent Infringement Lawsuit Against H&M Alpha Modus, Corp. is making headlines for filing a substantial patent infringement lawsuit against H&M Fashion USA, Inc. in the United States District Court for the Eastern District of Texas, Marshall Division. This legal action centers around allegations that H&M's retail operations in the U.S. are infringing...
Continue Reading